Vision Disorders - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

Vision Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Vision Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vision Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vision Disorders. Vision Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vision Disorders.
- A review of the Vision Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vision Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vision Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vision Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vision Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vision Disorders 7
Vision Disorders Therapeutics under Development by Companies 9
Vision Disorders Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Vision Disorders Therapeutics - Products under Development by Companies 14
Vision Disorders Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Vision Disorders Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Advanced Cell Technology, Inc. 17
Pfizer Inc. 18
Vision Disorders - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
ranibizumab - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
PF-05206388 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Ocular Programs - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Gene Therapy For Eye Diseases - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Vision Disorders Therapeutics - Drug Profile Updates 30
Vision Disorders Therapeutics - Dormant Products 34
Vision Disorders - Product Development Milestones 35
Featured News and Press Releases 35
Jun 04, 2012: Synta Presents Data Highlighting Superior Activity Of Ganetespib In Both Crizotinib-Sensitive And Resistant Models At ASCO Annual Meeting 35
May 24, 2012: RetroSense Therapeutics Completes Pre-IND Meeting For RST-001 35
Apr 17, 2012: ThromboGenics Resubmits BLA For Ocriplasmin With FDA 36
Mar 28, 2012: Canadian Agency For Drugs And Technologies In Health Recommends Provincial And Publicly Funded Drug Plans To Reimburse Novartis's Lucentis 36
Sep 14, 2011: Health Canada Approves Lucentis To Treat Vision Loss Resulting From Diabetic Macular Edema 37
Aug 18, 2011: Health Canada Approves Lucentis To Treat Vision Loss Resulting From Retinal Vein Occlusion 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40



List of Tables

Number of Products Under Development for Vision Disorders, H2 2013 7
Products under Development for Vision Disorders - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Early Clinical Stage Development, H2 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
F. Hoffmann-La Roche Ltd., H2 2013 16
Advanced Cell Technology, Inc., H2 2013 17
Pfizer Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 23
Vision Disorders Therapeutics - Drug Profile Updates 30
Vision Disorders Therapeutics - Dormant Products 34



List of Figures

Number of Products under Development for Vision Disorders, H2 2013 7
Products under Development for Vision Disorders - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Early Clinical Stage Products, H2 2013 12
Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 19
Assessment by Route of Administration, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Molecule Type, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 23



Companies Mentioned

F. Hoffmann-La Roche Ltd.
Advanced Cell Technology, Inc.
Pfizer Inc.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Fatty Liver Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Pathology Industry: Depression – Pipeline Review, H1 2012

Pathology Industry: Depression – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.